🔎 Trials Near Me

Home › Back Pain › NCT06827262

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

RecruitingObservational study

Who can join

Ages 18 and older · All sexes

Full eligibility criteria
Inclusion Criteria:

* Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).
* Signed a valid, IRB/EC-approved informed consent form.

Exclusion Criteria:

* Meets any contraindications per locally applicable Instructions for Use (IFU).

About the study

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

What is being tested

Sponsor: Boston Scientific Corporation · Participants: 1,500 · Started: Mar 26, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06827262

Locations in the U.S.

ArizonaFlagstaff Bone & Joint, Flagstaff
Innovative Pain and Wellness, Phoenix
CaliforniaMarinHealth Spine Institute, Larkspur
Stanford University Medical Center, Stanford
ConnecticutThe Spine Wellness Center in Westport, Westport
District of ColumbiaWashington Hospital Center, Washington D.C.
FloridaOrlando Regional Medical Center, Orlando
GeorgiaHorizon Clinical Research, LLC, Jasper
IllinoisIllinois Bone and Joint Institute, Barrington
KentuckyCommonwealth Pain and Spine, Lexington
LouisianaOchsner Clinic Foundation, New Orleans
MinnesotaiSpine Clinics, Maple Grove
CentraCare Health System, Saint Cloud
New YorkNew York Spine and Pain Specialists, Port Jefferson Station
University of Rochester, Rochester
Montefiore Medical Center, The Bronx
North CarolinaNovant Health Spine Specialists, Bermuda Run
PennsylvaniaAllegheny General Hospital, Pittsburgh
TexasCy-Pain and Spine, Houston
UtahUniversity of Utah Orthopaedic Center, Salt Lake City

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.